Michael J Wick
Overview
Explore the profile of Michael J Wick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Umeda M, Hiltenbrand R, Michmerhuizen N, Barajas J, Thomas M, Arthur B, et al.
medRxiv
. 2025 Feb;
PMID: 39974131
Leukemias with rearrangements exhibit heterogeneous phenotypes correlated to fusion partners, whereas the mechanism responsible for this heterogeneity is poorly understood. Through genome-wide mutational and transcriptional analyses of 177 -rearranged leukemias,...
2.
Capone E, Perrotti V, Cela I, Lattanzio R, Togni L, Rubini C, et al.
Oral Oncol
. 2023 Nov;
148:106635.
PMID: 37988837
Objectives: Adenoid cystic carcinoma (ACC) is a rare type of cancer that typically arises from glandular tissues, most commonly in the salivary glands. Although relatively rare, it represents a serious...
3.
Guimaraes L, Webber L, Gaio E, Junior D, Goncalves P, Wick M, et al.
Am J Cancer Res
. 2023 Feb;
13(1):143-160.
PMID: 36777521
Adenoid cystic carcinoma (ACC) patients face a highly infiltrative and metastatic disease characterized by poor survival rates and suboptimal response to available therapies. We have previously shown that sensitization of...
4.
Walker C, Chang H, Henegar L, Kashyap T, Shacham S, Sommer J, et al.
Front Oncol
. 2022 Sep;
12:808021.
PMID: 36059685
Chordoma is a rare cancer that grows in the base of the skull and along the mobile spine from remnants of embryonic notochord tissue. The cornerstone of current treatments is...
5.
Furman C, Puyang X, Zhang Z, Wu Z, Banka D, Aithal K, et al.
Mol Cancer Ther
. 2022 Jun;
21(6):890-902.
PMID: 35642432
Summary: H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors.
6.
Sudhan D, Guerrero-Zotano A, Won H, Ericsson P, Servetto A, Huerta-Rosario M, et al.
Cancer Cell
. 2020 Feb;
37(2):258-259.
PMID: 32049049
No abstract available.
7.
Sudhan D, Guerrero-Zotano A, Won H, Ericsson P, Servetto A, Huerta-Rosario M, et al.
Cancer Cell
. 2020 Jan;
37(2):183-199.e5.
PMID: 31978326
We developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance in HER2-mutant breast...
8.
Cocco E, Javier Carmona F, Razavi P, Won H, Cai Y, Rossi V, et al.
Sci Signal
. 2018 Oct;
11(551).
PMID: 30301790
Mutations in , the gene encoding epidermal growth factor receptor (EGFR) family member HER2, are common in and drive the growth of "HER2-negative" (not amplified) tumors but are rare in...
9.
Mandelbaum J, Shestopalov I, Henderson R, Chau N, Knoechel B, Wick M, et al.
J Exp Med
. 2018 Sep;
215(10):2673-2685.
PMID: 30209067
Pluripotent cells have been used to probe developmental pathways that are involved in genetic diseases and oncogenic events. To find new therapies that would target -driven tumors, we developed a...
10.
Kinneer K, Meekin J, Tiberghien A, Tai Y, Phipps S, Kiefer C, et al.
Clin Cancer Res
. 2018 Aug;
24(24):6570-6582.
PMID: 30131388
Purpose: Antibody-drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clinical use, and several are in development targeting solid and hematologic malignancies including multiple myeloma. Currently, there are...